Tatsuto Hamatani

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline.

ALSFRS-R decline rate prior to baseline is not useful for stratifying subsequent progression of functional decline.

Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

Published: February 07, 2024

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.

An Exploratory Trial of EPI-589 in Amyotrophic Lateral Sclerosis (EPIC-ALS): Protocol for a Multicenter, Open-Labeled, 24-Week, Single-Group Study.

Journal: JMIR research protocols

Published: August 24, 2022

Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI-589 in Healthy Participants.

Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI-589 in Healthy Participants.

Journal: Clinical pharmacology in drug development

Published: January 12, 2022

Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply.

Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 05, 2020

Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply.

Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: September 05, 2020

Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT4 receptor partial agonist, in healthy elderly and young subjects.

Pharmacokinetics, safety and metabolite profiling of minesapride, a novel 5-HT4 receptor partial agonist, in healthy elderly and young subjects.

Journal: Drug metabolism and pharmacokinetics

Published: March 24, 2020

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation.

Journal: Alimentary pharmacology & therapeutics

Published: March 13, 2020

Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial.

Efficacy and Safety of 5-HT4 Receptor Agonist Minesapride for Irritable Bowel Syndrome with Constipation in a Randomized Controlled Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: January 19, 2020

Thorough QT/QTc Study Shows That a Novel 5-HT4 Receptor Partial Agonist Minesapride Has No Effect on QT Prolongation.

Thorough QT/QTc Study Shows That a Novel 5-HT4 Receptor Partial Agonist Minesapride Has No Effect on QT Prolongation.

Journal: Clinical pharmacology in drug development

Published: November 17, 2019

Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.

Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.

Journal: Journal of diabetes investigation

Published: March 09, 2018

Showing 1-10 of 10

Last Updated: 09/26/2026